Nesta página
01PTCT preço
02Instantâneo
03Gráfico
05Sobre
06Desempenho
07Avaliação e rácios
14Lucros
15Fundamentos Completos
16Demonstrações
17Investidores institucionais (13F)
18Ativistas e proprietários de 5%+
19Executivos da empresa
20Participação em ETFs
21Consenso
22Pares
25Sinais de trading
26Minhas Métricas
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Jul 30, 2026
$63,46
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$61,23mínima 52 sem
$90,87máxima 52 sem
Capitalização de Mercado (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Receita (TTM)
$1.01B
seus distintivos
Intervalo 52 Semanas
$61–$91
Classificação do Analista
BUY
Preço-Alvo
$102
P/E
-117.5
ROE
20.6%
Margem de Lucro Líquido
-3.8%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
PTCT Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$63.46
Capitalização de Mercado (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Receita (TTM)
$1.01B
ROE (TTM)
20.6%
Dívida/Capital (MRQ)
-3.6
Intervalo 52 Semanas
$61–$91
PTCT Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre PTC Therapeutics, Inc. - Common Stock Visão geral da empresa da Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários991
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Fluxo de caixa livre$702M2016-12-31 → 2025-12-31
Margem líquida-3.8%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | PTCT | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5média 5A ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2média 5A ≈3.8 | ≈3.8 | 55.0 | Subvalorizado | |
| P/B (MRQ) | -32.0média 5A ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2média 5A ≈-5.5 | ≈-5.5 | · | · | |
| Preço / FCF (TTM) | -133.2média 5A ≈-10.8 | ≈-10.8 | · | · | |
| Preço / Fluxo de Caixa (TTM) | -173.4média 5A ≈-12.1 | ≈-12.1 | · | · | |
| EV / Receita (TTM) | 3.6média 5A ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.9média 5A ≈-8.4 | ≈-8.4 | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | -9.3 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | PTCT | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 12.5%média 5A ≈-25.9% | ≈-25.9% | -24.1% | Primeira linha | |
| Margem EBITDA (TTM) | 17.9%média 5A ≈-13.8% | ≈-13.8% | -24.1% | Primeira linha | |
| Margem de Impostos Pré-Tributação (TTM) | -6.6%média 5A ≈-43.8% | ≈-43.8% | -28.9% | Primeira linha | |
| Margem de Lucro Líquido (TTM) | -3.8%média 5A ≈-42.4% | ≈-42.4% | -38.1% | Primeira linha | |
| ROA (TTM) | -1.3%média 5A ≈-12.6% | ≈-12.6% | -27.7% | Primeira linha | |
| ROE (TTM) | 20.6%média 5A ≈-299.7% | ≈-299.7% | -40.8% | Fraco | |
| ROIC | 1044.7%média 5A ≈267.1% | ≈267.1% | -37.7% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | PTCT | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | -3.6média 5A ≈74.5 | ≈74.5 | · | · | |
| Índice de liquidez corrente (MRQ) | 3.4média 5A ≈2.1 | ≈2.1 | 8.3 | Baixa liquidez | |
| Índice de Liquidez Seca (MRQ) | 3.2média 5A ≈2.0 | ≈2.0 | 3.2 | Em linha | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | -3.2média 5A ≈65.1 | ≈65.1 | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | PTCT | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 114.5%média 5A ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 35.3%média 5A ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 35.4% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | PTCT | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.8média 5A ≈0.5 | ≈0.5 | 0.4 | Primeira linha | |
| Receivables Turnover (Giro de Contas a Receber) | 10.2média 5A ≈6.8 | ≈6.8 | 9.7 | Em linha | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$1.7M | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
105.2%
Próximo relatório
Nov 02, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 de Março de 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 de Dezembro de 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 de Setembro de 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 de Junho de 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 de Março de 2025 | $10.04 | $-0.22 | 4743.8% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $1.73B | $807M | $938M | $699M | $539M |
| Margem Operacional % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Lucro líquido | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Diluído | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Índice de liquidez corrente | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Índice de Liquidez Seca | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $702M | $-114M | $-187M | · | $-280M |
Investidores institucionais (13F) 403 declarantes · $8.6B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
403
Valor detido
$8.6B
Novas posições
76
Posições encerradas
43
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 76 (+7 vs trimestre anterior) | 43 (-7 vs trimestre anterior) | 140 (+3 vs trimestre anterior) | 114 (+10 vs trimestre anterior) | -1.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1.139.088.671 | 13.964.554 | 13,21% | Ações |
| VANGUARD GROUP INC | $668.691.300 | 8.803.203 | 7,75% | Ações |
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 7,33% | Ações |
| JANUS HENDERSON GROUP PLC | $489.997.100 | 7.193.433 | 5,68% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 4,66% | Ações |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 4,35% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $336.743.228 | 4.128.273 | 3,90% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 3,54% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $180.089.116 | 2.207.376 | 2,09% | Ações |
| TORONTO DOMINION BANK | $176.668.031 | 2.165.846 | 2,05% | Ações |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 1,85% | Ações |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 1,64% | Ações |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 1,63% | Ações |
| D. E. Shaw & Co., Inc. | $126.345.323 | 1.548.919 | 1,47% | Ações |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 1,42% | Ações |
| BANK OF AMERICA CORP /DE/ | $118.462.234 | 1.452.277 | 1,37% | Ações |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 1,36% | Ações |
| FMR LLC | $114.056.206 | 1.398.261 | 1,32% | Ações |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 1,28% | Ações |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,09% | Ações |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,09% | Ações |
| MORGAN STANLEY | $90.026.886 | 1.103.675 | 1,04% | Ações |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,01% | Ações |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 0,99% | Ações |
| FRANKLIN RESOURCES INC | $83.799.082 | 1.027.327 | 0,97% | Ações |
| Invesco Ltd. | $76.804.761 | 941.581 | 0,89% | Ações |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 0,87% | Ações |
| NORTHERN TRUST CORP | $71.783.966 | 880.029 | 0,83% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 0,75% | Ações |
| CITADEL ADVISORS LLC | $60.999.840 | 747.822 | 0,71% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 0,68% | Ações |
| Boston Partners | $58.606.553 | 718.574 | 0,68% | Ações |
| JUPITER ASSET MANAGEMENT LTD | $57.706.697 | 707.450 | 0,67% | Ações |
| MARSHALL WACE, LLP | $57.489.476 | 704.787 | 0,67% | Ações |
| JPMORGAN CHASE & CO | $56.073.502 | 684.042 | 0,65% | Ações |
| ARMISTICE CAPITAL, LLC | $53.836.200 | 660.000 | 0,62% | Opção de compra |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,62% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $52.017.434 | 637.704 | 0,60% | Ações |
| GOLDMAN SACHS GROUP INC | $50.430.408 | 618.247 | 0,58% | Ações |
| LOOMIS SAYLES & CO L P | $48.156.807 | 590.374 | 0,56% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,56% | Ações |
| Nuveen, LLC | $47.622.931 | 583.829 | 0,55% | Ações |
| Bank of New York Mellon Corp | $45.145.865 | 553.462 | 0,52% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $44.181.166 | 541.635 | 0,51% | Ações |
| VOYA INVESTMENT MANAGEMENT LLC | $43.992.251 | 539.319 | 0,51% | Ações |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,48% | Ações |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,47% | Ações |
| FEDERATED HERMES, INC. | $39.432.896 | 483.424 | 0,46% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,42% | Ações |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,41% | Ações |
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 declarações | 30 de Janeiro de 2015 | · | Declaração inicial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 declarações | 12 de Novembro de 2014 | · | Declaração inicial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 de Julho de 2013 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 37 insiders · 15 diretores · 20 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4 de Agosto de 2026 S | 383.868 | 0 | 13 | $-4.219.888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 de Janeiro de 2023 S | 54.903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 de Julho de 2026 S | 83.986 | 0 | 3 | $-652.864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 de Março de 2023 S | 38.925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 de Maio de 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 de Janeiro de 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 de Fevereiro de 2020 M | 6.744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 de Agosto de 2026 M | 105.272 | 0 | 63 | $-5.955.553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 de Julho de 2026 M | 60.299 | 0 | 62 | $-25.989.291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 de Junho de 2026 M | 70.199 | 0 | 5 | $-1.941.426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 de Junho de 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2 de Abril de 2026 S | 79.115 | 0 | 6 | $-1.081.515 |
| Mark Rothera | Chief Commercial Officer | 24 de Maio de 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 de Janeiro de 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 de Janeiro de 2016 A | 3.239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Conselheiro | 30 de Setembro de 2026 M | 22.500 | 0 | 2 | $-1.698.120 |
| Michael Schmertzler | Conselheiro | 17 de Setembro de 2026 S | 1.296.594 | 0 | 16 | $-6.313.453 |
| Hege Elisabeth Sollie-Zetlmayer | Conselheiro | 28 de Julho de 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Conselheiro | 9 de Julho de 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Jessica Caroline Chutter | Conselheiro | 24 de Março de 2026 A | 7.333 | 0 | 0 | $0 |
| Stephanie Okey | Conselheiro | 10 de Março de 2026 M | 8.000 | 0 | 3 | $-1.463.076 |
| Emma Reeve | Conselheiro | 5 de Janeiro de 2026 M | 10.666 | 0 | 15 | $-4.229.530 |
| Alethia Young | Conselheiro | 2 de Janeiro de 2026 A | 21.067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Conselheiro | 2 de Janeiro de 2026 A | 21.451 | 0 | 11 | $-2.912.018 |
| Jerome B Zeldis | Conselheiro | 2 de Janeiro de 2026 A | 22.500 | 0 | 0 | $0 |
| William F. Bell Jr. | Conselheiro | 15 de Fevereiro de 2024 A | 10.333 | 0 | 0 | $0 |
| Dawn Svoronos | Conselheiro | 9 de Junho de 2022 S | 29.017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Conselheiro | 3 de Janeiro de 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Conselheiro | 3 de Janeiro de 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Conselheiro | 3 de Janeiro de 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Conselheiro | 8 de Junho de 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Conselheiro | 16 de Março de 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Conselheiro | 25 de Junho de 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Detentor de 10% | 17 de Dezembro de 2013 S | 2.441.504 | 0 | 0 | $0 |
| David P Southwell | · | 2 de Janeiro de 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 de Abril de 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 de Junho de 2013 C | 2.256.882 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 68 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4.145 SH | 11 de Setembro de 2026 | Diário |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79.357 SH | 2 de Outubro de 2026 | Diário |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159.717 SH | 2 de Outubro de 2026 | Diário |
| MEDI · Harbor ETF Trust | 1,31% | 7.913 NS | 31 de Julho de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18.062 NS | 31 de Julho de 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22.852 SH | 2 de Outubro de 2026 | Diário |
| JSML · Janus Detroit Street Trust | 1,03% | 54.825 NS | 31 de Julho de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145.033 NS | 31 de Julho de 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 19 de Agosto de 2026 | Diário |
| VAMO · Cambria ETF Trust | 0,72% | 11.494 NS | 31 de Julho de 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5.120 NS | 31 de Julho de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46.006 NS | 31 de Julho de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 de Julho de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3.031 NS | 31 de Julho de 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613.266 SH | 11 de Setembro de 2026 | Diário |
| BRNY · EA Series Trust | 0,39% | 33.006 NS | 31 de Julho de 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 19 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5.891 SH | 2 de Outubro de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 19 de Agosto de 2026 | Diário |
| ESSC · Strategy Shares | 0,34% | 1.785 NS | 31 de Julho de 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664.357 SH | 11 de Setembro de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22.505 NS | 31 de Julho de 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25.676 NS | 31 de Julho de 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3.125 NS | 31 de Julho de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 19 de Agosto de 2026 | Diário |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19.797 NS | 31 de Julho de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.667 NS | 31 de Julho de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 19 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,18% | 2.118.779 SH | 11 de Setembro de 2026 | Diário |
| RSSL · Global X Funds | 0,18% | 39.691 NS | 31 de Julho de 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 de Julho de 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23.005 SH | 11 de Setembro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65.468 SH | 2 de Outubro de 2026 | Diário |
| LRGF · iShares Trust | 0,16% | 84.774 SH | 11 de Setembro de 2026 | Diário |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 19 de Agosto de 2026 | Diário |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51.459 NS | 31 de Julho de 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18.636 NS | 31 de Julho de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5.320 SH | 2 de Outubro de 2026 | Diário |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 de Julho de 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.600 NS | 31 de Julho de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224.327 NS | 31 de Julho de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952.071 SH | 19 de Agosto de 2026 | Diário |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1.902.509 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,08% | 211.842 SH | 19 de Agosto de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6.756 NS | 31 de Julho de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33.487 NS | 31 de Julho de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12.627 NS | 31 de Julho de 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18.932 SH | 2 de Outubro de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10.557 SH | 19 de Agosto de 2026 | Diário |
| ESML · iShares Trust | 0,06% | 22.893 SH | 11 de Setembro de 2026 | Diário |
| WSML · iShares Trust | 0,04% | 4.360 SH | 11 de Setembro de 2026 | Diário |
| TILT · FlexShares Trust | 0,01% | 4.108 NS | 31 de Julho de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.636.335 SH | 19 de Agosto de 2026 | Diário |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66.405 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6.819 SH | 19 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18.275 SH | 19 de Agosto de 2026 | Diário |
| ITOT · iShares Trust | 0,01% | 109.219 SH | 11 de Setembro de 2026 | Diário |
| IWV · iShares Trust | 0,01% | 22.686 SH | 10 de Setembro de 2026 | Diário |
| DFAC · Dimensional ETF Trust | 0,01% | 43.296 NS | 31 de Julho de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.090 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 de Julho de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 de Julho de 2026 | N-PORT |
| IJR · iShares Trust | · | 5.061.986 SH | 10 de Setembro de 2026 | Diário |
| IJT · iShares Trust | · | 784.746 SH | 9 de Setembro de 2026 | Diário |
| IWN · iShares Trust | · | 114.658 SH | 11 de Setembro de 2026 | Diário |
| XJR · iShares Trust | · | 11.464 SH | 31 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | · | 3.281 SH | 11 de Setembro de 2026 | Diário |
| SMLF · iShares Trust | · | 64.380 SH | 11 de Setembro de 2026 | Diário |
PTCT Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 21 analistas
COMPRA
Alvo mediano
$101.00
+59,2%
6 28,6%
Compra forte
11 52,4%
Compra
3 14,3%
Manter
1 4,8%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
14 analistas · 2026-10-01Alvo médio $101.79 +60,4%
← Abaixo de todos os alvos
Preço atual $63.46
Mín$70.00
Média$101.79
Máx$137.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Nenhum sinal aberto no momento — nenhum cartão está preenchido, e isso é honesto.
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Jul 30, 2026